Long-term use of the CentriMag<sup>®</sup> Ventricular Assist System as a right ventricular assist device: a case report

Griffith, Kendall C.; Jenkins, Eric; Stulak, John M.; Paugh, Theron A.; Pagani, Francis D.

doi:10.1177/0267659111424634

Cited by 25 publications

(15 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CentriMag temporary centrifugal VAD has proven safety and clinical effectiveness in left and/or right ventricular and ECMO support for long-term use periods exceeding 300 days (22). Pump-related hemolysis and adverse event rates are consistently low, with outcomes depending predominantly upon patient status rather than VAD complications.…”

Section: Discussionmentioning

confidence: 99%

The CentriMag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices

et al. 2014

View full text Add to dashboard Cite

Implantable ventricular assist devices (VADs) have proven efficient in advanced heart failure patients as a bridge-to-transplant or destination therapy. However, VAD usage often leads to infection, bleeding, and thrombosis, side effects attributable to the damage to blood cells and plasma proteins. Measuring hemolysis alone does not provide sufficient information to understand total blood damage, and research exploring the impact of currently available pumps on a wider range of blood cell types and plasma proteins such as von Willebrand factor (vWF) is required to further our understanding of safer pump design. The extracorporeal CentriMag (Thoratec Corporation, Pleasanton, CA, USA) has a hemolysis profile within published standards of normalized index of hemolysis levels of less than 0.01 g/100 L at 100 mm Hg but the effect on leukocytes, vWF multimers, and platelets is unknown. Here, the CentriMag was tested using bovine blood (n = 15) under constant hemodynamic conditions in comparison with a static control for total blood cell counts, hemolysis, leukocyte death, vWF multimers, microparticles, platelet activation, and apoptosis. The CentriMag decreased the levels of healthy leukocytes (P < 0.006), induced leukocyte microparticles (P < 10−5), and the level of high molecular weight of vWF multimers was significantly reduced in the CentriMag (P < 10−5) all compared with the static treatment after 6 h in vitro testing. Despite the leukocyte damage, microparticle formation, and cleavage of vWF multimers, these results show that the CentriMag is a hemocompatible pump which could be used as a standard in blood damage assays to inform the design of new implantable blood pumps.

show abstract

Section: Discussionmentioning

confidence: 99%

The CentriMag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices

et al. 2014

View full text Add to dashboard Cite

show abstract

“…51 Right ventricular assist devices (RVADs) can be implanted either surgically 52 or percutaneously. 53 Paracorporeal RVADs can be used for weeks or even months, 54 but they are only approved for up to 4 weeks. These devices can easily be combined with oxygenators when needed.…”

Section: Consider Transfer To Hospital With Possibility For Ecmo/mechmentioning

confidence: 99%

Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology

Harjola

Mebazaa

Čelutkienė

et al. 2016

European J of Heart Fail

530

427

View full text Add to dashboard Cite

Acute right ventricular (RV) failure is a complex clinical syndrome that results from many causes. Research efforts have disproportionately focused on the failing left ventricle, but recently the need has been recognized to achieve a more comprehensive understanding of RV anatomy, physiology, and pathophysiology, and of management approaches. Right ventricular mechanics and function are altered in the setting of either pressure overload or volume overload. Failure may also result from a primary reduction of myocardial contractility owing to ischaemia, cardiomyopathy, or arrhythmia. Dysfunction leads to impaired RV filling and increased right atrial pressures. As dysfunction progresses 227to overt RV failure, the RV chamber becomes more spherical and tricuspid regurgitation is aggravated, a cascade leading to increasing venous congestion. Ventricular interdependence results in impaired left ventricular filling, a decrease in left ventricular stroke volume, and ultimately low cardiac output and cardiogenic shock. Identification and treatment of the underlying cause of RV failure, such as acute pulmonary embolism, acute respiratory distress syndrome, acute decompensation of chronic pulmonary hypertension, RV infarction, or arrhythmia, is the primary management strategy. Judicious fluid management, use of inotropes and vasopressors, assist devices, and a strategy focusing on RV protection for mechanical ventilation if required all play a role in the clinical care of these patients. Future research should aim to address the remaining areas of uncertainty which result from the complexity of RV haemodynamics and lack of conclusive evidence regarding RV-specific treatment approaches.

show abstract

“…Extended use of CentriMag has been described previously (1). However, unlike previous reports, where the RVAD inflow cannula was inserted in the right atrium (1), this patient underwent minimally invasive RVAD implantation that facilitated early extubation, mobilization, reduced bleeding risks, and would have facilitated RVAD explantation without necessitating resternotomy. As recovery of the right ventricle may occur late after LVAD implantation, this RVAD implantation technique may be considered for patients in cardiogenic shock with the potential of right ventricular recovery.…”

Section: Discussionmentioning

confidence: 87%

Case Report of Extended “Temporary” Use of Levitronix CentriMag Right Ventricular Assist Device

2012

View full text Add to dashboard Cite

Long-term use of the CentriMag^® Ventricular Assist System as a right ventricular assist device: a case report

Cited by 25 publications

References 16 publications

The CentriMag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices

The CentriMag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices

Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology

Case Report of Extended “Temporary” Use of Levitronix CentriMag Right Ventricular Assist Device

Contact Info

Product

Resources

About

Long-term use of the CentriMag® Ventricular Assist System as a right ventricular assist device: a case report

Cited by 25 publications

References 16 publications

The CentriMag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices

The CentriMag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices

Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology

Case Report of Extended “Temporary” Use of Levitronix CentriMag Right Ventricular Assist Device

Contact Info

Product

Resources

About

Long-term use of the CentriMag^® Ventricular Assist System as a right ventricular assist device: a case report